Want to see CYTK full AI Analyst Report?

Cytokinetics (CYTK) Stock Forecast & Price Target

1,301 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CYTK Analyst Ratings

Strong Buy

14 Buy

2 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Cytokinetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CYTK Stock 12 Month Forecast

Average Price Target

$106.53

▲(59.70% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $106.53 with a high forecast of $140.00 and a low forecast of $83.00. The average price target represents a 59.70% change from the last price of $66.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","141":"$141","59.25":"$59.3","86.5":"$86.5","113.75":"$113.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.53333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$106.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$83.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,59.25,86.5,113.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.26,89.47076923076924,93.68153846153847,97.8923076923077,102.10307692307693,106.31384615384616,110.52461538461539,114.73538461538462,118.94615384615385,123.15692307692308,127.36769230769231,131.57846153846154,135.78923076923076,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.26,86.89641025641026,88.53282051282052,90.16923076923078,91.80564102564102,93.44205128205128,95.07846153846154,96.7148717948718,98.35128205128206,99.98769230769231,101.62410256410257,103.26051282051282,104.89692307692307,{"y":106.53333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.26,85.08615384615385,84.91230769230769,84.73846153846154,84.5646153846154,84.39076923076924,84.21692307692308,84.04307692307692,83.86923076923077,83.69538461538461,83.52153846153847,83.34769230769231,83.17384615384616,{"y":83,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.84,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.43,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.61,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.35,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.68,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.26,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$140.00

Average Price Target$106.53

Lowest Price Target$83.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Serge Belanger

Needham

$102

Buy

52.90%

Upside

Reiterated

06/29/26

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Cytokinetics (NASDAQ: CYTK)

Ashwani Verma

UBS

$115

Buy

72.39%

Upside

Upgraded

06/29/26

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Cytokinetics (NASDAQ: CYTK)

Salim Syed

Mizuho Securities

$100→$118

Buy

76.89%

Upside

Reiterated

06/23/26

Mizuho Securities Keeps Their Buy Rating on Cytokinetics (CYTK)

Jason Zemansky

Bank of America Securities

$67→$83

Hold

24.42%

Upside

Reiterated

06/16/26

Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK) and American Well (NYSE: AMWL)

Maxwell Skor

Morgan Stanley

$103

Buy

54.40%

Upside

Reiterated

06/16/26

Analyst Reiterates Buy on Cytokinetics, Citing Aficamten’s Best-in-Class Profile and Safety Edge, Keeps $103 Price Target Unchanged

Eric Joseph

Citi

$99

Buy

48.40%

Upside

Reiterated

06/16/26

Cytokinetics Maintained at Buy on Competitive Validation and Differentiation; $99 Price Target Reaffirmed

Tessa Romero

J.P. Morgan

$97

Buy

45.41%

Upside

Reiterated

06/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joseph Pantginis

H.C. Wainwright

$140

Buy

109.86%

Upside

Reiterated

05/12/26

Cytokinetics price target raised to $140 from $136 at H.C. WainwrightCytokinetics price target raised to $140 from $136 at H.C. Wainwright

Yanan Zhu

Wells Fargo

$95→$105

Buy

57.40%

Upside

Reiterated

05/07/26

Cytokinetics (CYTK) Gets a Buy from Wells Fargo

Unknown Analyst

Raymond James

Not Ranked

Raymond James

―

Hold

―

Reiterated

05/06/26

Raymond James Reaffirms Their Hold Rating on Cytokinetics (CYTK)

Yasmeen Rahimi

Piper Sandler

$107

Buy

60.40%

Upside

Reiterated

05/06/26

Piper Sandler Reaffirms Their Buy Rating on Cytokinetics (CYTK)

Srikripa Devarakonda

Truist Financial

$92→$106

Buy

58.90%

Upside

Reiterated

05/06/26

Cytokinetics price target raised to $106 from $92 at TruistCytokinetics price target raised to $106 from $92 at Truist

James Condulis

Stifel Nicolaus

$98→$108

Buy

61.89%

Upside

Assigned

05/06/26

Cytokinetics price target raised to $108 from $98 at StifelCytokinetics price target raised to $108 from $98 at Stifel

Leonid Timashev

RBC Capital

$101→$119

Buy

78.38%

Upside

Reiterated

05/05/26

RBC Capital Reaffirms Their Buy Rating on Cytokinetics (CYTK)

Paul Choi

Goldman Sachs

$101

Buy

51.40%

Upside

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Strata Critical Medical (NASDAQ: SRTA) and Cytokinetics (NASDAQ: CYTK)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Serge Belanger

Needham

$102

Buy

52.90%

Upside

Reiterated

06/29/26

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Cytokinetics (NASDAQ: CYTK)

Ashwani Verma

UBS

$115

Buy

72.39%

Upside

Upgraded

06/29/26

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Cytokinetics (NASDAQ: CYTK)

Salim Syed

Mizuho Securities

$100→$118

Buy

76.89%

Upside

Reiterated

06/23/26

Mizuho Securities Keeps Their Buy Rating on Cytokinetics (CYTK)

Jason Zemansky

Bank of America Securities

$67→$83

Hold

24.42%

Upside

Reiterated

06/16/26

Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK) and American Well (NYSE: AMWL)

Maxwell Skor

Morgan Stanley

$103

Buy

54.40%

Upside

Reiterated

06/16/26

Analyst Reiterates Buy on Cytokinetics, Citing Aficamten’s Best-in-Class Profile and Safety Edge, Keeps $103 Price Target Unchanged

Eric Joseph

Citi

$99

Buy

48.40%

Upside

Reiterated

06/16/26

Cytokinetics Maintained at Buy on Competitive Validation and Differentiation; $99 Price Target Reaffirmed

Tessa Romero

J.P. Morgan

$97

Buy

45.41%

Upside

Reiterated

06/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joseph Pantginis

H.C. Wainwright

$140

Buy

109.86%

Upside

Reiterated

05/12/26

Cytokinetics price target raised to $140 from $136 at H.C. WainwrightCytokinetics price target raised to $140 from $136 at H.C. Wainwright

Yanan Zhu

Wells Fargo

$95→$105

Buy

57.40%

Upside

Reiterated

05/07/26

Cytokinetics (CYTK) Gets a Buy from Wells Fargo

Unknown Analyst

Raymond James

Not Ranked

Raymond James

―

Hold

―

Reiterated

05/06/26

Raymond James Reaffirms Their Hold Rating on Cytokinetics (CYTK)

Yasmeen Rahimi

Piper Sandler

$107

Buy

60.40%

Upside

Reiterated

05/06/26

Piper Sandler Reaffirms Their Buy Rating on Cytokinetics (CYTK)

Srikripa Devarakonda

Truist Financial

$92→$106

Buy

58.90%

Upside

Reiterated

05/06/26

Cytokinetics price target raised to $106 from $92 at TruistCytokinetics price target raised to $106 from $92 at Truist

James Condulis

Stifel Nicolaus

$98→$108

Buy

61.89%

Upside

Assigned

05/06/26

Cytokinetics price target raised to $108 from $98 at StifelCytokinetics price target raised to $108 from $98 at Stifel

Leonid Timashev

RBC Capital

$101→$119

Buy

78.38%

Upside

Reiterated

05/05/26

RBC Capital Reaffirms Their Buy Rating on Cytokinetics (CYTK)

Paul Choi

Goldman Sachs

$101

Buy

51.40%

Upside

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Strata Critical Medical (NASDAQ: SRTA) and Cytokinetics (NASDAQ: CYTK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

3 Months

Tessa RomeroJ.P. Morgan

Success Rate

16/24 ratings generated profit

Average Return

+26.60%

Copying Tessa Romero's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +26.60% per trade.

1 Year

Joseph PantginisH.C. Wainwright

Success Rate

17/17 ratings generated profit

Average Return

+55.97%

Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +55.97% per trade.

2 Years

Joseph PantginisH.C. Wainwright

Success Rate

17/17 ratings generated profit

Average Return

+77.44%

Copying Joseph Pantginis's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +77.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CYTK Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CYTK has received 23 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CYTK average Analyst price target in the past 3 months is 106.53.

Each month's total comprises the sum of three months' worth of ratings.

CYTK Financial Forecast

CYTK Earnings Forecast

Next quarter’s earnings estimate for CYTK is -$1.64 with a range of -$2.02 to -$1.26. The previous quarter’s EPS was -$1.67. CYTK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Sales Forecast

Next quarter’s sales forecast for CYTK is $16.69M with a range of $8.38M to $27.71M. The previous quarter’s sales results were $19.36M. CYTK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Stock Forecast FAQ

What is CYTK’s average 12-month price target, according to analysts?

Based on analyst ratings, Cytokinetics’s 12-month average price target is 106.53.

What is CYTK’s upside potential, based on the analysts’ average price target?

Cytokinetics has 59.70% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CYTK a Buy, Sell or Hold?

Cytokinetics has a consensus rating of Strong Buy which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.

What is Cytokinetics’s price target?

The average price target for Cytokinetics is 106.53. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $83.00. The average price target represents 59.70% Increase from the current price of $66.71.

What do analysts say about Cytokinetics?

Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of CYTK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cytokinetics (CYTK) Stock Forecast & Price Target

CYTK Analyst Ratings

CYTK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cytokinetics

CYTK Analyst Recommendation Trends

CYTK Financial Forecast

CYTK Earnings Forecast

CYTK Sales Forecast

CYTK Stock Forecast FAQ

Detailed List of Analyst Forecasts